The authors of a new study of prolonged-release oxycodone/naloxone (OXN PR) in patients with Parkinson’s disease assert that their work provides important new insights into the efficacy of the treatment for the severe pain that can accompany the condition. The results appear online ahead of print this week in Lancet Neurology. Although the primary endpoint of the study—improved average pain scores with OXN PR vs placebo at week 16—were not met, secondary endpoint data at other timepoint assessments indicated positive treatment effects, according to the researchers. The phase II, 16-week, randomized, double-blind study was funded by Mundipharma GmbH & Co.KG.
A press release on the research points out that Parkinson’s disease is the second most common neurodegenerative disease after Alzheimer’s disease, with pain as a common comorbidity, affecting approximately 60% of patients. Pain is one of the nonmotor symptoms of Parkinson’s disease associated with a depressed mood and reduced quality of life. Disease related pain is typically treated by increasing the doses of dopaminergic therapy. Principal investigator Claudia Trenkwalder, MD, asserted “This study adds to the very limited knowledge base on the efficacy and safety of opioid-based treatment of patients with Parkinson’s disease suffering from complex pain. The encouraging secondary endpoint data suggest that further studies may help to uncover the potential role of OXN PR in this patient population.”
Read the press release from Mundipharma GmbH & Co.KG here.
The journal article abstract may be read here.